The medical school has made substantial investment in cancer research and BSMS is emerging as a national and international leader in this field.
BSMS cancer research uses innovative approaches to bring findings from the bench to the bedside. Key cancer research teams at BSMS include:
The haemato-oncology (blood cancer) team, in which experimental and computational biologists work together with clinical haematologists and University of Sussex based researchers to create more personalised and targeted therapies for patients.
Read more about HRG here >
The psycho-oncology team, which aims to make cancer treatment better for patients by using patient reported outcomes, improving communication between clinicians and patients, and reducing the symptoms and side-effects of cancer and cancer treatments.
Read more about Shore-C here >
BSMS’s cancer research is supported by teams working on biology of significance for cancer, such as RNA Biology, and cancer outcomes/epidemiology and by the Sussex drug discovery centre. Cancer research at BSMS is also uniquely positioned to benefit from the world-class scientific Genome Damage and Stability Centre (GDSC) research institute at the university of Sussex.
BSMS has strong links to the clinic, and has invested in important cancer facilities including the Clinical Investigation and Research Unit at the Royal Sussex County Hospital and the purpose-built Clinical Imaging Sciences Centre (CISC) at the University of Sussex. First-class translational research facilities are available on the Falmer campus and BSMS with new clinical research facilities recently established at the hospital site as part of the 3T-redevelopment programme.